Modified transplant preparation for advanced leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new conditioning regimen before stem cell transplant for people in the blast phase of chronic myeloid leukemia (CML). It aims to help patients whose leukemia has progressed to a more aggressive stage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with blast-phase CML, meaning at least 20% blasts in your blood or bone marrow, or blasts found outside the bone marrow.
- You are 18 years or older.
- Your liver, kidney, pancreas, and heart function are within safe limits.
- You have a performance status of 0-2, meaning you are up and doing daily activities with little or no help.
- You are HIV, hepatitis B, and hepatitis C negative.
- You have not had a prior stem cell transplant and do not have other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination to help people with relapsed or refractory acute myeloid leukemia (AML) get ready for a stem cell transplant. The goal is to make the transplant more effective and improve outcomes.
This trial tests a new combination of chemotherapy drugs before a stem cell transplant for people with acute myeloid leukemia (AML) in first remission who are not very fit or have other health problems. The goal is to make the transplant safer for these patients.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This trial tests a risk-adapted conditioning regimen (chemotherapy and/or radiation given before transplant) for people with certain blood cancers or bone marrow disorders who need a stem cell transplant from a donor. The goal is to tailor the conditioning strength to each patient’s risk, which may help improve outcomes and reduce side effects.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.